Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
FDA Approves Elranatamab for Multiple Myeloma
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory ...
Elranatamab | Pfizer Oncology Development Website
Thuốc Elranatamab điều trị bệnh u tủy đa tái phát hoặc kháng trị
Elranatamab Improves Survival in Phase 3 Trial for Relapsed/Refractory ...
Elranatamab Under Review for Relapsed or Refractory Multiple Myeloma
Elranatamab là chất gì? Có công dụng gì? Được tìm mua ở đâu?
Pivotal MagnetisMM-3 Trial Aims to Add Elranatamab in Multiple Myeloma ...
The Results of MagnetisMM-1: Elranatamab on Relapsed Myeloma
记住所有FDA生物药 | BCMA×CD3双抗 | Elrexfio® Elranatamab | 多发性骨髓瘤 - 知乎
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple ...
Elranatamab in Combination with Daratumumab for Patients with Relapsed ...
Elranatamab in relapsed or refractory multiple myeloma: phase 2 ...
Elranatamab - Single-patient Expanded Access - Multiple Myeloma ...
Elranatamab Myeloma Trials
Study of Elranatamab for Treating Relapsed or Refractory Multiple ...
Elranatamab + Daratumumab + Lenalidomide for Multiple Myeloma Clinical ...
FDA Grants Priority Review to Elranatamab for R/R Multiple Myeloma
(PDF) Elranatamab in relapsed or refractory multiple myeloma: phase 2 ...
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R ...
Elranatamab in Multiple Myeloma - CancerConnect
FDA Grants Priority Review to Elranatamab for Relapsed/Refractory ...
Elranatamab treatment in a multiple myeloma patient undergoing renal ...
Elranatamab Shows Efficacy of BCMA-Targeted Therapy in Multiple Myeloma
Elranatamab Improves Progression-Free Survival in Multiple Myeloma ...
Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple ...
Elranatamab & Pharmacists: Optimizing Multiple Myeloma Care – Archyde
MagnetisMM-3 Results: Elranatamab in Relapsed Myeloma | Int'l Myeloma Fn
Elranatamab efficacy in MagnetisMM-3 compared with real-world control ...
Elranatamab receives breakthrough therapy designation for advanced ...
Real-world outcomes with elranatamab in multiple myeloma: A multi ...
Elranatamab for Black Patients with Relapsed Multiple Myeloma [ASH 2023 ...
Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal ...
Elranatamab – Application in Therapy and Current Clinical Research
FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
Elranatamab Demonstrates Sustained Efficacy with Reduced Dosing ...
Table 1 from Elranatamab in Japanese patients with relapsed/refractory ...
Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 ...
Elranatamab provides durable clinical response in relapsed multiple ...
(PDF) Elranatamab efficacy in MagnetisMM-3 compared with real-world ...
Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted ...
Elranatamab (ELREXFIO®) [Acthera]
Elranatamab Approaches EU Approval for Heavily Pretreated Relapsed ...
Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in ...
Elranatamab Biosimilar Antibody (Recombinant BCMA-CD3 Bispecific ...
Leveraging quantitative systems pharmacology modeling for elranatamab ...
Elranatamab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma ...
Full article: Cost per responder for teclistamab and elranatamab in ...
Figure 2 from Elranatamab in Japanese patients with relapsed/refractory ...
Elranatamab approved at fourth line and beyond - Myeloma UK
Fixed-Duration Elranatamab Consolidation Enhances MRD Negativity ...
Phase 1 Findings for Elranatamab in Relapsed or Refractory MM | Urban ...
MagnetisMM-3: Long-Term Efficacy & Safety of Less Frequent Elranatamab ...
Table 4 from Elranatamab in Japanese patients with relapsed/refractory ...
Real-World Elranatamab Is Active in Relapsed/Refractory Multiple ...
Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 ...
Figure 1 from Elranatamab in Japanese patients with relapsed/refractory ...
Elranatamab - Upcoming Myeloma Therapy - YouTube
(PDF) P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB ...
BCMA/CD3 Bispecific Antibodies for Multiple Myeloma (MM) | Biopharma PEG
FDA-Granted Priority Review for Pfizer’s Anti-CD3/BCMA Bispecific ...
ELREXFIO (elranatamab) for the Treatment of Multiple Myeloma, USA
从16种双抗产品的上市顺序、获批适应症及历年销售看双抗结构的演变_生物器材网
Elrexfio (elranatamab) dosing, indications, interactions, adverse ...
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 ...
多发性骨髓瘤，辉瑞双特异性抗体Elranatamab获FDA优先审评 - 知乎
ELREXFIO (elranatamab-bcmm) | International Myeloma Foundation
Daratumumab (Darzalex®) Treatment Guide - Myeloma UK
Frontiers | Bispecific antibodies for the treatment of relapsed ...
BCMA/CD3丨从FDA第五款双抗看全球进展 2022年10月25日，FDA加速批准 强生 BCMA/CD3双抗TECVAYLI ...
Multiple Myeloma Updates
Hematologic Malignancies | CCO
Frontiers | Therapeutic strategies to enhance immune response induced ...
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody ...
Elranatamab-bcmm Approved for Adult Patients With Relapsed or ...
Stage of Development
A Novel Two‐Part Mixture Model for the Incidence and Time Course of ...
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance ...
Multiple Myeloma
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA ...
Emerging Bispecific T-Cell Engagers in Myeloma: Promises and Hurdles
Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple ...
BCMA-Directed Bispecific Antibodies for Multiple Myeloma: Practical ...
Frontiers | Bispecific antibody targets and therapies in multiple myeloma
Canada | Multiple Myeloma Clinical Trials
NICE recommends new multiple myeloma treatment, Elrexfio® (elranatamab ...
Elranatamab-bcmm receives accelerated approval by FDA for multiple myeloma
FDA Greenlights Erlanatamab for Relapsed or Refractory Multiple Myeloma ...
ELREXFIO (elranatamab-bcmm) Approved By FDA | International Myeloma ...
Elrexfio (elranatamab-bcmm) for multiple myeloma | Rare Cancer News
PPT - BCMACD3 Bispecific Antibodies for Multiple Myeloma (MM ...
Frontiers | Relapsed refractory multiple myeloma with CNS involvement ...
从上市双抗产品看双抗结构的演变医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Talquetamab in multiple myeloma | Haematologica
Optimizing Bispecific Antibody Therapy in Multiple Myeloma: A Resource ...
辉瑞的Elranatamab获得FDA和EMA申请受理|多发性骨髓瘤|EMA|CD3|细胞|药物|-健康界
从Linvoseltamab最新临床数据公布，看BCMA/CD3双抗研究进展 - 知乎
全球第二款！FDA授予辉瑞CD3/BCMA双特异性抗体优先审评医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
British Journal of Haematology | Wiley Online Library
These highlights do not include all the information needed to use ...
Frontiers | The silent signals: emerging safety concerns in bispecific ...
Updated Results of a Matching-Adjusted Indirect Comparison of ...
ELREXFIO REMS | elranatamab-bcmm
CD3/BCMA Bispecific Antibody for Multiple Myeloma Treatment - Protheragen
